Trial Profile

A Phase 2 trial of SYN-2510/IMM2510 monotherapy in second-line non-squamous and squamous NSCLC

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palverafusp alfa (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Jan 2026 According to an Instil Bio media release, company has decided to discontinue clinical development of AXN-2510, and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. have entered into an agreement to terminate their license and collaboration arrangement for AXN-2510 and AXN-27M.
18 Sep 2024 New trial record
16 Sep 2024 According to Instil Bio media release,IND submission is targeted for late 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com